Effects of tablets containing Lactobacillus salivarius WB21 and hinokitiol on inflammation of gingiva, subjective symptoms in oral cavity, and numbers of bacteria in saliva.

Effects of tablets containing Lactobacillus salivarius WB21 and hinokitiol on inflammation of gingiva, subjective symptoms in oral cavity, and numbers of bacteria in saliva. - Effects of tablets containing Lactobacillus salivarius WB21 and hinokitiol on oral environment.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000033906

Enrollment

Registered

2018-08-27

Start date

2018-08-03

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

oral environment

Interventions

The participants in the test group ingest tablets containing Lactobacillus salivarius WB21 and hinokitiol for 4 weeks. The dose is maintained at 1 tablet 3 times a day, taken orally after eating and m

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Healthy adults. 2. Brushing teeth twice a day using only toothbrush. 3. Average of modified gingival index is equal to or more than0.5. 4. Having something subjective symptoms in questionnaire about subjective symptoms in the oral cavity.

Exclusion criteria

Exclusion criteria: 1. A person diagnosed as suffering from any dental disease by a dentist. 2. Person who underwent periodontal treatment or treatment with antibacterial agent within 3 months prior to the start of the study. 3. Persons who received maintenance such as dental plaque and calculus removal at the dental office within 3 months prior to the start of the test. 4. Smokers. 5. Persons using dentures. 6. Persons who used lactic acid bacteria-containing dentifrice, mouthwash and oral care supplement within 1 month prior to the start of the test. 7. Persons who have a history of systemic diseases such as gastrointestinal disease (gastritis, stomach ulcer, colitis, etc), severe respiratory diseases such as diabetes, liver disease, kidney disease, asthma, severe heart disease, malignant tumor. 8. Milk and hinokitiol allergies. 9. Pregnant or possibly pregnant or breast-feeding. 10. Those who have participated in other clinical trials within one month prior to agree participation or those who intend to participate in other clinical trials after obtaining participation agreement for this study. 11. Persons who judged that the investigator is inappropriate as the subject.

Design outcomes

Primary

Measure	Time frame
modified gingival index (2 weeks and 4 weeks after starting ingestion)	—

Secondary

Measure	Time frame
subjective oral symptoms (2 weeks and 4 weeks after starting ingestion) numbers of bacteria in saliva (2 weeks and 4 weeks after starting ingestion)	—

Countries

Japan

Contacts

Public ContactNao Taniguchi

Fukuoka Dental College Department of Preventive and Public Health Dentistry

naojsz@college.fdcnet.ac.jp092-801-0411

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026